The scientific background of the DARPin® technology has been summarized in various reviews. For further information, please see below, or contact us.

Clinical DARPin® product candidates

MP0250 pre-clinical data have been published in 2017 for the first time. Researchers presented clinical data from the company’s Phase 1 clinical trial at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Mass., USA in November 2015 for the first time and in every subsequent year.

MP0250

Fiedler, U. et al. (2017), Oncotarget 8: 98371-98383.

Binz, H.K. et al. (2017), MAbs 9: 1262-1269.

Rao, L. et al. (2018), Oncotarget 9: 13366-13381.

Designed Repeat Proteins

Stumpp, M.T. et al. (2007), DARPins Review. Curr. Opin. Drug. Discov. Devel. 10:153-159.

Binz, H. K. et al. (2005), DARPins Review. Nat. Biotechnol. 23: 1257-1268.

Souied, E. et al. (2014), Phase I of Abicipar in wet AMD. Am. J. Ophthalmol.

Campochiaro, P.A. et al. (2013), Phase I of Abicipar in DME. Am. J. Ophthalmol.

Natural Repeat Proteins

Dong, R. et al. (2013). HuR: a promising therapeutic target for angiogenesis. Angiogenisis.

Martin, S.A. et al (2010). Mismatch Repair Therapeutic Targeting of the DNA Mismatch Repair Pathway. Clin Cancer Res.

Jost, C. et al. (2013). Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2. Structure.